Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine

Double Blind Randomized Control Trial of Inhaled Isopropyl Alcohol Vapors Versus Inhaled Eucalyptus Scent for the Treatment of Nausea Associated With Acute Migraine

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05175521

Enrollment

Registered

2022-01-03

Start date

2021-11-11

Completion date

2026-04-01

Last updated

2026-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Keywords

Nausea, Isopropyl alcohol, Eucalyptus, Aromatherapy, Vapors

Brief summary

The goal of this study is to compare the efficacy and adverse events of inhaled isopropyl alcohol vapor (IAV) versus placebo (inhaled eucalyptus scent (IES) (1:20 dilution in mineral oil) for treating nausea associated with acute migraine attacks.

Detailed description

The main goal of this study is to examine the efficacy of (nausea reduction and time to use of other anti-nausea medications) and side effects of inhaled isopropyl alcohol vapor (IAV) for treating nausea among migraine patients using a double blind randomized control methodology. IAV is being compared inhaled eucalyptus scent (IES) (1:20 dilution in mineral oil) which has not shown benefit for treating nausea or migraine and is therefore considered placebo in this study.

Interventions

OTHEREucalyptus Oil Scent

Eucalyptus oil in mineral (1:20) will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack

OTHERIsopropyl Alcohol Vapors

Isopropyl Alcohol 70% will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Patients 18 to 65 years old with nausea associated migraines at least twice per month

Exclusion criteria

* Patients \<18 or \>65 years old * Patients without a diagnosis of acute migraine

Design outcomes

Primary

Measure	Time frame	Description
Change of Severity of Nausea on Nausea Scale	½ hour or to the end of treatment	Change in Nausea, modified visual analog score from 0-10 with 10 severe nausea with vomiting, 5 moderate nausea, 1 mild nausea and 0 no nausea.

Secondary

Measure	Time frame	Description
Side effects associated with interventional substance	½ hour, but likely less than 2 hours	Patient written report
Use of anti-nausea medication/Time to use of anti-nausea medication	½ hour or to the end of treatment	Did using IAV vs eucalyptus oil change the time until use of oral anti-emetic?
Time to Clinically Relevant Nausea Change	½ hour or to the end of treatment	Did IAV vs eucalyptus oil reduce the amount of time the patient experienced nausea with their migraine?

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJill Rau, MD, PhD

HonorHealth Research Institute

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 18, 2026